-
Je něco špatně v tomto záznamu ?
Reviewing Antiviral Research against Viruses Causing Human Diseases - a Structure-Guided Approach
A. Sikdar, R. Gupta, E. Boura
Jazyk angličtina Země Spojené arabské emiráty
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antivirové látky farmakologie terapeutické užití MeSH
- infekce virem zika * farmakoterapie MeSH
- lidé MeSH
- virové nemoci * farmakoterapie MeSH
- virus zika * MeSH
- viry * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The smallest of all the pathogens, viruses, have continuously been the foremost strange microorganisms. Viral infections can cause extreme sicknesses as evidenced by the HIV/AIDS widespread or the later Ebola or Zika episodes. Apprehensive framework distortions are also regularly observed as consequences of numerous viral infections. Besides, numerous viral infections are of oncoviruses, which can trigger different types of cancer. Nearly every year, a modern infectious species emerges, debilitating the world population with an annihilating episode. Subsequently, there is a need to create antivirals to combat such rising infections. From the discovery of the antiviral drug Idoxuridine in 1962 to the revelation of Baloxavir marboxil (Xofluza) that was approved by the FDA in 2018, the whole process and criteria of creating antivirals have changed significantly. In this article, different auxiliary science strategies are described that can serve as a referral for therapeutic innovation.
Department of Neurology Duke University Medical Center Durham North Carolina DC USA
University of Tennessee Health Science Center Memphis TN 38163 USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019512
- 003
- CZ-PrNML
- 005
- 20220804135725.0
- 007
- ta
- 008
- 220720s2022 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1874467214666210804152836 $2 doi
- 035 __
- $a (PubMed)34348638
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Sikdar, Arunima $u University of Tennessee Health Science Center, Memphis, TN 38163, USA $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 245 10
- $a Reviewing Antiviral Research against Viruses Causing Human Diseases - a Structure-Guided Approach / $c A. Sikdar, R. Gupta, E. Boura
- 520 9_
- $a The smallest of all the pathogens, viruses, have continuously been the foremost strange microorganisms. Viral infections can cause extreme sicknesses as evidenced by the HIV/AIDS widespread or the later Ebola or Zika episodes. Apprehensive framework distortions are also regularly observed as consequences of numerous viral infections. Besides, numerous viral infections are of oncoviruses, which can trigger different types of cancer. Nearly every year, a modern infectious species emerges, debilitating the world population with an annihilating episode. Subsequently, there is a need to create antivirals to combat such rising infections. From the discovery of the antiviral drug Idoxuridine in 1962 to the revelation of Baloxavir marboxil (Xofluza) that was approved by the FDA in 2018, the whole process and criteria of creating antivirals have changed significantly. In this article, different auxiliary science strategies are described that can serve as a referral for therapeutic innovation.
- 650 _2
- $a antivirové látky $x farmakologie $x terapeutické užití $7 D000998
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a virové nemoci $x farmakoterapie $7 D014777
- 650 12
- $a viry $7 D014780
- 650 12
- $a virus zika $7 D000071244
- 650 12
- $a infekce virem zika $x farmakoterapie $7 D000071243
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gupta, Rupali $u Department of Neurology, Duke University Medical Center, Durham, North Carolina, DC, USA
- 700 1_
- $a Boura, Evzen $u University of Tennessee Health Science Center, Memphis, TN 38163, USA $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 773 0_
- $w MED00180210 $t Current molecular pharmacology $x 1874-4702 $g Roč. 15, č. 2 (2022), s. 306-337
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34348638 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135719 $b ABA008
- 999 __
- $a ok $b bmc $g 1822916 $s 1170755
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 15 $c 2 $d 306-337 $e - $i 1874-4702 $m Current molecular pharmacology $n Curr Mol Pharmacol $x MED00180210
- LZP __
- $a Pubmed-20220720
